Drug manufacturing companies Cipla and Glenmark are recalling their medicines from the American market due to manufacturing issues. Cipla’s New Jersey-based subsidiary has recalled 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, reported the US Food and Drug Administration (USFDA). Cipla USA has recalled these lots of medicines due to “short fill”. According to USFDA, the quantity of medicine in these medicine pouches was less than the prescribed limit. Apart from this, there were also drops of liquid in the pouches. These medicines have been manufactured in India. These medicines were manufactured in a SEZ plant in Indore city of India. These medications are used to help control the symptoms of lung diseases such as asthma, chronic bronchitis, and emphysema. Glenmark also recalls high blood pressure medicine Glenmark Pharma has recalled 3,264 bottles of capsules of diltiazem hydrochloride, a medicine used to control high blood pressure. Glenmark’s US-based branch Glenmark Pharmaceuticals Inc. is withdrawing the drug due to some shortcomings in its manufacturing. The company started the recall from April 17, 2024. According to the USFDA, the recalled drugs were not expected to cause any major harm. Cipla is the second largest pharmaceutical company in India. Cipla is the second largest pharmaceutical company in India. It has manufacturing units in 47 locations across the world. It supplies its products in 86 countries of the world. The market cap of the company is Rs 1.15 lakh crore. Sun Pharma is the country’s largest pharma company. India is the largest supplier of generic medicines. India is the largest supplier of generic medicines, manufacturing 60,000 different generic brands of medicines in 60 medical categories. India accounts for 20% of the total supply of medicines in the world. Medicines manufactured in India are supplied to more than 200 countries around the world including Japan, Australia, Western Europe and America.
